Cellular accumulation, subcellular localization, and cytotoxicity of the radiobioconjugate were evaluated with MDA-MB-361 and SK-BR-3 human breast cancer cell lines overexpressing HER2 receptors, as well as with MDA-MB-231, which has HER2-negative status. This evidence concerns the gene ERBB2 and breast carcinoma.